Advertisement

Topics

Nonmelanomatous Skin Cancer - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Nonmelanomatous Skin Cancer - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 44-page report is available in PDF from $2000.

Nonmelanomatous Skin Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Nonmelanomatous Skin Cancer - Pipeline Review, H1 2015’, provides an overview of the Nonmelanomatous Skin Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nonmelanomatous Skin Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nonmelanomatous Skin Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nonmelanomatous Skin Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Nonmelanomatous Skin Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Nonmelanomatous Skin Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nonmelanomatous Skin Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nonmelanomatous Skin Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Nonmelanomatous Skin Cancer - Overview 7
Pipeline Products for Nonmelanomatous Skin Cancer - Comparative Analysis 8
Nonmelanomatous Skin Cancer - Therapeutics under Development by Companies 9
Nonmelanomatous Skin Cancer - Therapeutics under Investigation by Universities/Institutes 10
Nonmelanomatous Skin Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Nonmelanomatous Skin Cancer - Products under Development by Companies 14
Nonmelanomatous Skin Cancer - Products under Investigation by Universities/Institutes 15
Nonmelanomatous Skin Cancer - Companies Involved in Therapeutics Development 16
Advancell 16
EcoBiotics Limited 17
LEO Pharma A/S 18
Spherium Biomed S.L. 19
Nonmelanomatous Skin Cancer - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ANs-40 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ANS-401 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ANS-403 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
EBC-46 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
OXT-328 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules to Activate Protein Kinase C for Dermatology and Cancer - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Inhibit PLK1 for Cutaneous Squamous Cell Carcinoma - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
SP-12054 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Vaccine for HPV Associated Skin Cancer - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Nonmelanomatous Skin Cancer - Recent Pipeline Updates 40
Nonmelanomatous Skin Cancer - Dormant Projects 41
Nonmelanomatous Skin Cancer - Discontinued Products 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

For more information open Nonmelanomatous Skin Cancer - Pipeline Review, H1 2015.

SKU: GMDHC6623IDB

Original Article: Nonmelanomatous Skin Cancer - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Nonmelanomatous Skin Cancer - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....